| Original language | English |
|---|---|
| Pages (from-to) | 1027-1030 |
| Number of pages | 4 |
| Journal | Journal of Oncology Pharmacy Practice |
| Volume | 25 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jun 1 2019 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Oncology Pharmacy Practice, Vol. 25, No. 4, 01.06.2019, p. 1027-1030.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma
AU - Martin, Peter
AU - Goy, Andre
AU - Ramchandren, Radhakrishnan
AU - Ferrante, Lucille
AU - Londhe, Anil
AU - McGowan, Tracy
AU - Bartlett, Nancy L.
N1 - Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Nancy L. Bartlett reports having received institutional research funding for conduct of clinical trials from Janssen and Pharmacyclics. Radhakrishnan Ramchandren reports having received research funding from Janssen and Pharmacyclics. Peter Martin reports having consulted for AstraZeneca, Celgene, Gilead, Janssen, Karyopharm, and Sandoz. Andre Goy reports having consulted for Celgene, Pharmacyclics/J&J, Acerta, and Takeda; received institutional research funding (Hackensack University Medical Center) from Celgene, Pharmacyclics/ J&J, and Genentech; received honoraria from Celgene, Takeda, Pharmacyclics/J&J, and Acerta; served on speakers bureaus for Takeda and Pharmacyclics/J&J; received writing support from Takeda; and reports advisory committee membership for Pharmacyclics/J&J, Takeda, Acerta, Celgene, and Infinity. Lucille Ferrante, Anil Londhe, and Tracy McGowan are employees of Janssen Scientific Affairs, LLC, and own stock in Johnson & Johnson, of which Janssen is a wholly owned subsidiary. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by funding from Janssen Global Services, LLC.
PY - 2019/6/1
Y1 - 2019/6/1
UR - http://www.scopus.com/inward/record.url?scp=85062027279&partnerID=8YFLogxK
U2 - 10.1177/1078155219831435
DO - 10.1177/1078155219831435
M3 - Letter
C2 - 30786822
AN - SCOPUS:85062027279
SN - 1078-1552
VL - 25
SP - 1027
EP - 1030
JO - Journal of Oncology Pharmacy Practice
JF - Journal of Oncology Pharmacy Practice
IS - 4
ER -